CYP19A1 and breast carcinoma: Indeed, the death rate has dropped from its peak for female breast cancer by 40% [1], probably due to an adequate combination of early screening programs and improvement in adjuvant therapy, such as the aromatase inhibitors (AIs)—commonly used in estrogen-positive tumors to prevent recurrence [4].